文献速递神经肌肉病

POEMS综合征的临床特征、风险因素与结局:纵向队列研究

Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study.
PubMed 文献 · Neurology · 2020-06-30

诊断时中位多系统特征数为7,96%有神经病,35%需轮椅或卧床;5年生存率90%、10年82%,5年和10年无进展生存率分别为65%和53%。多变量分析显示未接受自体干细胞移植、非血液学反应和非血管内皮生长因子反应是进展或死亡的显著风险因素,并据此开发了风险评分。

要点

  • POEMS综合征诊断延迟常见,54%初诊被误诊为CIDP。
  • 诊断时35%患者已需轮椅或卧床,治疗后神经功能评分改善。
  • 未接受自体干细胞移植、非血液学反应和非VEGF反应提示进展或死亡风险高。

核心结论

  • POEMS综合征是一种罕见多系统疾病,诊断延迟且就诊时神经功能差,但治疗结局较好。
  • 可识别死亡或进展高风险患者,可能有助于更积极监测和影响管理。

研究设计与样本

  • 1998年至2019年3月的回顾性纵向队列研究,共7184人月随访时间。

主要发现

  • 从症状出现到诊断平均15个月(范围1-77),54%患者最初被误诊为慢性炎性脱髓鞘性多发性神经病。
  • 诊断时中位多系统特征数为7;96例(96%)表现为神经病,其中93例(93%)呈长度依赖性,75例(75%)有疼痛。
  • 诊断时35%患者需轮椅或卧床,中位总体神经限制评分(ONLS)为6,治疗后改善至3(p < 0.05)。
  • 5年生存率90%,10年82%;5年和10年无进展生存率分别为65%和53%。
  • 多变量分析显示未接受自体干细胞移植、非血液学反应和非血管内皮生长因子反应是预测进展或死亡的显著风险因素。

关键数值与推荐

  • 风险因素被纳入开发风险评分,以实现高风险和低风险病例的分层。

临床怎么用

  • 对疑似POEMS综合征患者应提高诊断意识,减少误诊为CIDP。
  • 治疗可改善神经功能,应关注自体干细胞移植及血液学、VEGF反应。
  • 可利用风险评分识别高风险患者,加强监测和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin lesions) is a paraneoplastic disorder resulting in severe neurologic disability. Understanding the clinical, laboratory, neurophysiologic, and histopathologic features as well as treatment responses of POEMS will assist in more accurate and timely diagnosis, risk stratification, and effective management. METHODS: This was a retrospective longitudinal cohort study from 1998 to March 2019, with 7,184 person-months of follow-up time. Hospital databases were used to collate presenting features, investigations, therapies, and response. RESULTS: One hundred patients were included with a median follow-up time of 59 months (range, 1-252). Mean symptom onset to diagnosis was 15 months (range, 1-77), with 54% of patients initially misdiagnosed with chronic inflammatory demyelinating polyneuropathy. Median number of multisystem features at diagnosis was 7. Ninety-six (96%) presented with neuropathy, which was length-dependent in 93 (93%) and painful in 75 (75%). At diagnosis, 35% of patients were wheelchair or bedbound, with median Overall Neuropathy Limitation Score of 6, improving to 3 following treatment (p < 0.05). Five-year survival was 90% and 82% at 10 years, with 5- and 10-year progression-free survival of 65% and 53%. Nontreatment with autologous stem cell transplantation, nonhematologic response, and non-vascular endothelial growth factor response are significant risk factors in multivariate analysis to predict progression or death. Risk factors are incorporated to develop a risk score enabling stratification of high- and low-risk cases. CONCLUSIONS: POEMS syndrome is a rare multisystem condition with delayed diagnosis and poor neurologic function at presentation. Therapy has favorable outcomes. Patients at high risk of death or progression can be identified, which may allow for more active monitoring and influence management.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Keddie S, Foldes D, Caimari F, et al. Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study. Neurology. 2020. PMID: 32606227. doi:10.1212/WNL.0000000000009940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。